Home › Research › Drug development
GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX
Wen-Teng Lee. Journal of the American Society of Nephrology, 2025-10-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
GLP-1RA use was associated with lower risk of dementia (HR 0.80, 95% CI 0.71–0.91) and Alzheimer’s disease (HR 0.76, 95% CI 0.59–0.98) compared to DPP4is. Other outcomes showed no significant differences. GLP-1RAs may reduce dementia and Alzheimer’s disease risk in advanced CKD, supporting potential neuroprotective effects beyond glycemic control. Funding: Government Support – Non-U.S.Neurodegenerative Outcomes Comparison from GLP-1RAs and DPP4is - Clinical Outcomes GLP-1RAs (n = 12,351) DDP4is (n = 12,351) GLP-1RAs vs. DDP4is Dementia 455 (3.7) 562 (4.6) 0.80 (0.71–0.91) (p=0.001) Alzheimer 109 (0.9) 142 (1.1) 0.76 (0.59–0.98) (p=0.033) Vascular dementia 173 (1.4) 182 (1.5) 0.95 (0.77–1.16) (p=0.591) Frontotemporal dementia 10 (0.1) 14 (0.1) 0.64 (0.28–1.48) (p=0.294) Dementia with Lewy bodies 11 (0.1) 15 (0.1) 0.74 (0.34–1.61) (p=0.443) Parkinson 178 (1.4) 177 (1.4) 1.00 (0.81–1.23) (p=0.992) Extrapyramidal and movement disorders 1,057 (8.6) 994 (8.0) 1.06 (0.97–1.16) (p=0.178)
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 12,351 participants. In this real-world study of people with diabetes and advanced chronic kidney disease, those taking GLP-1 receptor agonists had a lower risk of dementia and Alzheimer's disease diagnoses than those taking DPP4 inhibitors. Reported effect size: HR 0.80; HR 0.76.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lee, W.-T. (2025). GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2025rdy8v05v
Vancouver
Lee W.-T. GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.2025rdy8v05v.
BibTeX
@article{lee2025-01baa622,
author = {Lee, Wen-Teng},
title = {{GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX}},
journal = {Journal of the American Society of Nephrology},
year = {2025},
doi = {10.1681/asn.2025rdy8v05v},
url = {https://doi.org/10.1681/asn.2025rdy8v05v}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- GLP-1RA use was associated with lower risk of dementia (HR 0.80, 95% CI 0.71–0.91) and Alzheimer’s disease (HR 0.76, 95% CI 0.59–0.98) compared to DPP4is.
- Other outcomes showed no significant differences.
- GLP-1RAs may reduce dementia and Alzheimer’s disease risk in advanced CKD, supporting potential neuroprotective effects beyond glycemic control.
- Funding: Government Support – Non-U.S.Neurodegenerative Outcomes Comparison from GLP-1RAs and DPP4is - Clinical Outcomes GLP-1RAs (n = 12,351) DDP4is (n = 12,351) GLP-1RAs vs.
- DDP4is Dementia 455 (3.7) 562 (4.6) 0.80 (0.71–0.91) (p=0.001) Alzheimer 109 (0.9) 142 (1.1) 0.76 (0.59–0.98) (p=0.033) Vascular dementia 173 (1.4) 182 (1.5) 0.95 (0.77–1.16) (p=0.591) Frontotemporal dementia 10 (0.1) 14 (0.1) 0.64 (0.28–1.48) (p=0.294) Dementia with Lewy bodies 11 (0.1) 15 (0.1) 0.
Why it matters
In this real-world study of people with diabetes and advanced chronic kidney disease, those taking GLP-1 receptor agonists had a lower risk of dementia and Alzheimer's disease diagnoses than those taking DPP4 inhibitors. No significant differences were found for other conditions such as vascular dementia or Parkinson's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants12,351
- Effect sizeHR 0.80; HR 0.76
- Evidence strengthModerate
How this study scored 47/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Society of Nephrology) |
| Journal's citation record | 3 / 4 | Journal of the American Society of Nephrology: journal h-index 370 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 12,351 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Wen-Teng Lee holds only 5 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Shin Kong WHS Memorial Hospital: institution h-index 142 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.